Recently, Sichuan Yuanda Shuyang Pharmaceutical, a wholly-owned subsidiary of Grand Life Science Group, has entered into an exclusive license agreement with Neoletix (Beijing), under which Sichuan Yuanda Shuyang Pharmaceutical will be granted an exclusive right to develop, register, and commercialize human recombinant factor VIII (project code: NX01) in the Greater China region.

NX01 is a human recombinant B-zone deleted factor VIII, which is used for hemorrhage control and prophylaxis in patients with hemophilia A. Hemophilia A is a common inherited bleeding disorder. Low levels or complete absence of coagulation factor VI in the blood is the cause of hemophilia A. A common clinical treatment is coagulation factor V replacement therapy. Coagulation factor VI can be obtained from human blood or produced by recombination in vitro. According to statistics and prediction from the National Bureau of Statistics and the World Federation of Hemophilia, the number of hemophiliacs in China has reached 140,000 people. As human coagulation factor V is in short supply and expensive, hemophiliacs in China are mostly treated on an as-needed basis, with only 2-3% of the total number of patients receiving prophylactic treatment. The further promotion of prophylactic treatment in China in the future will bring further expansion of the hemophilia drug market size. Given the tight and expensive global supply of coagulation factors, the hemophilia field is in dire need of high-yield and affordable Factor VIII products. NX01 is based on Neoletix's patented technology of large molecule protein expression, the yield of which has been significantly improved compared with similar products. The reduction in cost will increase the accessibility of the drug and change the plight of hemophiliacs who have difficulty in accessing medication for both prevention and treatment. It is expected that this product will fundamentally change the treatment and prevention pattern of hemophilia patients in China, thus greatly improving the life quality of patients. The introduction of NX01 is an important step taken by Sichuan Yuanda Shuyang Pharmaceutical from traditional blood product products to the layout of recombinant blood product pipelines, opening up a new track for the layout of hemophilia product pipelines. Under the terms of the agreement, Neoletix will receive an initial payment from Sichuan Yuanda Shuyang Pharmaceutical as well as milestone payments and tiered royalties based on clinical progress, registration and commercialization milestones achieved for the NX01 project.

About Beijing Neoletix Biological Technology Co., Ltd.

Beijing Neoletix Biological Technology Co., Ltd. is an international innovative biopharmaceutical company with research centers in the U.S. and the Beijing Economic-Technological Development Area in China. Neoletix has a long history of focusing on novel drugs for hemostasis, anti-thrombosis and rare diseases, especially in the use of traditional or novel coagulation factors for the treatment of inherited or acquired bleeding disorders (e.g., hemophilia A and B), acute traumatic hemorrhage (e.g., trauma or surgery), thrombotic disorders (e.g., deep venous thrombosis, stroke, etc.), etc. Meanwhile, Neoletix also focuses on the field of stem tumor targeted therapy and has developed a variety of anti-tumor drugs based on the platform of targeted nano-antibodies, which are characterized by the ability to target stem malignant tumors, including unlabeled malignant tumor cells, opening up a new avenue for tumor treatment.

About Grand Life Science Group Co., Ltd.

Grand Life Science Group Co., Ltd. (hereinafter referred to as "Grand Life Science") is a modernized and comprehensive pharmaceutical enterprise group with a domestic base and an international outlook. With the idea of building a pharmaceutical industrial system integrating R&D, production and sales, and the concept of independent, group and internationalized innovative R&D, Grand Life Science focuses on five major therapeutic areas, i.e. immunity and infection, perioperative and critical care, hematology, digestion and metabolism, and wound management, striving to provide patients around the world with comprehensive and industry-wide services ranging from health management, disease prevention to disease treatment. With a global vision to study the future trends of the industry, Grand Life Science aims at the unmet clinical needs both at home and abroad. Relying on the technology platforms of vaccines, micro-ecological drugs, ecombinant macromolecules, blood products, polymer materials, pharmaceuticals, collagenase, etc., Grand Life Science has set up R&D centers and production bases in more than ten cities, including Beijing, Chengdu, Hangzhou, Shenyang, Wuhan, Chongqing, Nanjing, Zhengzhou, Yantai, and Anshan, and is committed to the R&D and production of high-end blood products, new recombinant vaccines, new generation of live bacterial formulations, nano-targeted formulations, degradable medical devices and high-value APIs, etc.